Tuberc Respir Dis.  2009 Dec;67(6):517-527.

Bacteriologic Analysis of Expectorated Sputum in Patient with Bronchiectasis

• Seo KW
• Hwang SJ
• Sung SJ
• Kim SJ
• Do GW
• Hur SJ
• Lim KH
• Hong SH
• Kim DM
• Jeon JB
• Jegal Y
• Choi SW
• Kwon WJ
• Jeong J
• Ahn JJ

Abstract

BACKGROUND
Bronchiectasis (BE) remains a rare respiratory disease in Korea. This retrospective study was done to investigate the potential pathogenic microorganisms (PPMs) that cause in patients with BE, through the use of sputum specimens. METHODS: One hundred eleven adult patients, who had undergone chest computed tomography (CT), sputum gram stain/culture, and BE detected by chest CT, were included in this study. Sputum adequacy was determined by using Murray-Washington classification. RESULTS: The mean (+/-SD) age of patients was 60.9 (+/-14.0). The number of PPMs was 167 (67%) in the total 248 isolated organisms. The most frequent PPMs were P. aeruginosa (23.4%), K. pneumoniae (10.5%), and S. aureus (8.4%). The proportion of adequate sputum (AS) was 25.8% in the total sputum specimens. The patients with AS were 41 (37%) and the patients with inadequate sputum (IS) were 70 (63%). The proportion of P. aeruginosa was higher in AS compared to that of IS (44% vs. 19%, p=0.004). The BE score was also higher in P. aeruginosa (+) patients compared to that of P. aeruginosa (-) patients (10.8 vs. 7.6, p=0.001). CONCLUSION: Although the proportion of AS in the total sputum was low, PPMs were isolated in most patients with BE. It is likely that P. aeruginosa was isolated in AS and AS patients had higher BE scores.

Keyword

Bronchiectasis; Sputum; Microbiology; Bacteriology

MeSH Terms

Adult
Bacteriology
Bronchiectasis
Humans
Korea
Pneumonia
Retrospective Studies
Sputum
Thorax

Figure

• 

  Figure 1 Total patients with isolated P. aeruginosa. Black bar (■) represents adequate sputum specimen (AS) and white bar (□) represents inadequate sputum specimen (IS). No: number.

• 

  Figure 2 Antimicrobial resistance in the P. aeruginosa isolates for each antibiotics (◆). AMK: amikin; ATM: aztreonam; FEP: cefepime; CTZ: ceftazidime; CIP: ciprofloxacin; GEN: gentamicin; IMP: imipenem; PIP: piperacillin; TCA: Ticarcillin+Clavulanate; TOB: tobramycin.

• 

  Figure 3 Antimicrobial resistance in the K. pneumoniae isolates for each antibiotics (●). AMK: amikin; AMP: ampicillin; AMP/SBT: ampicillin/sulbactam; ATM: aztreonam; CFZ: cefazolin; FEP: cefepime; CFX: cefoxitin; CFT: ceftriaxone; CIP: ciprofloxacin; ESBL: extended spectrum β-lactamase; GEN: gentamicin; IMP: imipenem; PIP/TZC: piperacillin/tazocin; TOB: tobramycin.

Reference

1. Swartz MN. Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM, editors. Chapter 132. Bronchiectasis. Fishman's pulmonary diseases and disorders. 1998. 3rd ed. New York: McGraw-Hill;2045–2070.

2. Barker AF. Bronchiectasis. N Engl J Med. 2002. 346:1383–1393.

3. Rho YH, Kim YW, Park CS, Lee YH, Kim SY, Kim KY, et al. Clinical review of 147 cases of bronchiectasis. Korean J Med. 1982. 25:155–163.

4. Chung HY, Cho DI, Yoo JI, Rhu MS. Clinical studies on relationship with sinusitis and bronchiectasis. Tuberc Respir Dis. 1978. 25:165–169.

5. Shin YG, Im JS, Choi HH. Clinical study of bronchiectasis. Korean J Thorac Cardiovasc Surg. 1993. 26:294–297.

6. The annual prevalence day of each chronic illness in Korea (Population per person in 2001) [Internet]. Korea National Statistical Office. c2009. Daejeon: Korea National Statistical Office;Available from: http://www.kosis.kr/http://www.kosis.kr/.

7. Ho PL, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest. 1998. 114:1594–1598.

8. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007. 101:1633–1638.

9. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007. 44:Suppl 2. S27–S72.

10. Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975. 50:339–344.

11. Geckler RW, Gremillion DH, McAllister CK, Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol. 1977. 6:396–399.

12. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000. 31:347–382.

13. Lee JH, Kim YK, Kwag HJ, Chang JH. Relationships between high-resolution computed tomography, lung function and bacteriology in stable bronchiectasis. J Korean Med Sci. 2004. 19:62–68.

14. Clarke L, Latta PD. Isenberg HD, editor. Paratechnical processing of specimens for aerobic bacteriology. Clinical microbiology procedures handbook. 2008. 2nd ed. Washington: ASM Press;3311–3329.

15. Cabello H, Torres A, Celis R, El-Ebiary M, Puig de la Bellacasa J, Xaubet A, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J. 1997. 10:1137–1144.

16. Murray A, Mostafa S, van Saene H. Soutenbeek CP, van Saene HKF, editors. Essentials in clinical microbiology. Baillieres's clinical anaesthesiology. 1991. 1st ed. London: Bailliere Tindall;1–23.

17. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999. 14:1015–1022.

18. Chow AW. Mandell GL, Bennett JE, Dolin R, editors. Chapter 57. Infections of the oral cavity, neck, and head. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 2005. 6th ed. Philadelphia: Churchill Livingstone;787–710.

19. Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM, Flower CD. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax. 1996. 51:914–918.

20. Barker AF, Bardana EJ Jr. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis. 1988. 137:969–978.

21. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest. 1999. 115:1033–1040.

22. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989. 321:863–868.

23. Lee JY, Song JW, Hong SB, Oh YM, Lim CM, Lee SD, et al. Prevalence of NTM pulmonary infection in the patients with bronchiectasis. Tuberc Respir Dis. 2004. 57:311–319.

24. Chung SW, Chung HK. Clinical evaluation of the bronchiectasis. Korean J Thorac Cardiovasc Surg. 1995. 28:1007–1013.

25. Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002. 57:15–19.

26. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995. 108:955–961.

27. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000. 162:1277–1284.

28. Laurenzi GA, Potter RT, Kass EH. Bacteriologic flora of the lower respiratory tract. N Engl J Med. 1961. 265:1273–1278.

29. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007. 176:356–361.

30. Rosell A, Monso E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005. 165:891–897.

31. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999. 116:40–46.

32. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med. 1998. 157:1498–1505.

33. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J. 2004. 23:685–691.

34. Wilson R. Bacteria, antibiotics and COPD. Eur Respir J. 2001. 17:995–1007.

35. Pang JA, Cheng A, Chan HS, Poon D, French G. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalveolar lavage. Am Rev Respir Dis. 1989. 139:14–17.

36. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995. 152:1316–1320.

37. Roson B, Carratala J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis. 2000. 31:869–874.

38. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother. 2008. 62:Suppl 1. i1–i9.

39. Costerton JW. The etiology and persistence of cryptic bacterial infections: a hypothesis. Rev Infect Dis. 1984. 6:Suppl 3. S608–S616.

40. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999. 37:1771–1776.